Docoh
Loading...

PTPI Petros Pharmaceuticals

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.

Company profile

Ticker
PTPI
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Metuchen Pharmaceuticals, LLC • TIMM Medical, Inc. • Pos-T-Vac, LLC ...
IRS number
851410058

PTPI stock data

(
)

Calendar

16 Aug 21
28 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 11.03M 11.03M 11.03M
Cash burn (monthly) 1.18M 1.43M (positive/no burn)
Cash used (since last report) 4.64M 5.62M n/a
Cash remaining 6.39M 5.41M n/a
Runway (months of cash) 5.4 3.8 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Oct 21 John D Shulman Common Stock, par value $0.0001 per share Buy Acquire P Yes No 1.715 1,661,807 2.85M 5,057,771
18 Oct 21 John D Shulman Warrant Common Stock Buy Acquire P Yes No 1.715 1,661,807 2.85M 1,661,807
11 May 21 Andrew Gesek Stock Option Common Stock Grant Acquire A No No 3.21 75,000 240.75K 75,000
11 May 21 Mitchell Arnold Stock Option Common Stock Grant Acquire A No No 3.21 50,000 160.5K 50,000
8 Apr 21 Silverman Joshua Stock Option Common Stock Grant Acquire A No No 3.18 50,000 159K 50,000
8 Apr 21 John D Shulman Stock Option Common Stock Grant Acquire A No No 3.18 50,000 159K 50,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

50.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 25 22 +13.6%
Opened positions 6 6
Closed positions 3 6 -50.0%
Increased positions 6 5 +20.0%
Reduced positions 5 2 +150.0%
13F shares
Current Prev Q Change
Total value 5.56M 6.77M -17.9%
Total shares 4.94M 5.11M -3.3%
Total puts 0 0
Total calls 31.25K 31.25K
Total put/call ratio
Largest owners
Shares Value Change
John D Shulman 3.4M $0 0.0%
Intracoastal Capital 579K $2.55M 0.0%
Shay Capital 238.76K $747K -7.0%
NorthRock Partners 219.19K $686K -35.1%
Vanguard 107.5K $336K +21.2%
CM Management 100K $313K +122.2%
Renaissance Technologies 54.89K $172K -70.4%
Acorn Financial Advisory Services 50.2K $157K -19.9%
Platform Technology Partners 44K $138K NEW
Citadel Advisors 35.06K $110K -1.2%
Largest transactions
Shares Bought/sold Change
Renaissance Technologies 54.89K -130.66K -70.4%
NorthRock Partners 219.19K -118.34K -35.1%
CM Management 100K +55K +122.2%
Platform Technology Partners 44K +44K NEW
Spire Wealth Management 0 -44K EXIT
Emfo 28K +28K NEW
FNY Investment Advisers 0 -20K EXIT
Vanguard 107.5K +18.8K +21.2%
Shay Capital 238.76K -17.91K -7.0%
VIRT Virtu Financial 14.36K +14.36K NEW

Financial report summary

?
Competition
IQVIA
Management Discussion
  • The impact on our results of operations of the COVID-19 pandemic and related changes in economic conditions, including changes to consumer spending resulting from the rapid rise in local and national unemployment rates, are highly uncertain and, in many instances, outside of our control. The duration and severity of the direct and indirect effects of the pandemic continue to evolve and in ways that are difficult to anticipate. There are numerous uncertainties related to the COVID-19 pandemic that have impacted our ability to forecast our future operations as a company. The extent to which the COVID-19 pandemic, and the emergence of any new variants, will affect our business, financial position and operating results in the future cannot be predicted with certainty; however, any such impact could be material. The COVID-19 pandemic could also increase the degree to which our results, including the results of our business segments, fluctuate in the future.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg

Proxies

No filings